PAXIL CR

LOE Approaching

paroxetine hydrochloride

NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7

Mechanism of Action

(MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).

Indications (1)

Clinical Trials (5)

NCT01339247Phase 1Completed

Paxil CR Bioequivalence Study Brazil - Fed Administration

Started Oct 2009
60 enrolled
Depressive Disorder
NCT01316926Phase 1Completed

Paxil CR Bioequivalence Study Brazil

Started Sep 2009
60 enrolled
Depressive Disorder
NCT00749359Phase 1Completed

PAXIL CR Bioequivalence Study

Started Jul 2008
166 enrolled
Depressive Disorder
NCT00557622Phase 2Terminated

Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

Started Jan 2008
5 enrolled
Post-Traumatic Stress DisorderStress Disorders, Post-Traumatic
NCT00841698Phase 1Completed

Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions

Started Oct 2002
50 enrolled
Healthy